ARMATA PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
ARMATA PHARMACEUTICALS, INC. (ARMP) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $163.90 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-08-12
- 2026-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $163.90M.
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $254.92M.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $153.86M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $48.09M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2026-06-30 | $163.90M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $254.92M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $153.86M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $48.09M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $33.45M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $27.69M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $32.90M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $41.36M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $48.26M 10-Q · filed 2025-08-12 |
| 2023-12-31 | $58.63M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |